Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05232409 · ClinicalTrials.gov registry record · Phase 1
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
A Phase 1 study of Metastatic Solid Tumor and Cancer Metastatic, sponsored by Valley Health System.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT05232409 is a Phase 1 study of Metastatic Solid Tumor and Cancer Metastatic that is actively recruiting participants, run by Valley Health System. The registered enrollment target is 72 participants, below the 191-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05232409, a Phase 1 study of Metastatic Solid Tumor and Cancer Metastatic, is actively recruiting participants, sponsored by Valley Health System.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the research is to determine the highest dose of an oral compound called zeaxanthin that can be safely taken each day in patients with advanced cancer, the toxicity profile of zeaxanthin, and the dose of zeaxanthin to use in future cancer clinical trials.
Conditions Studied
Interventions
- BIOLOGICAL Zeaxanthin
- COMBINATION_PRODUCT Zeaxanthin Plus Pembrolizumab
Study Locations (1)
New Jersey
- The Valley Hospital-Luckow Pavilion - Paramus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-04-17 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05232409
The ClinicalTrials.gov registry entry for NCT05232409 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 191-participant average among 52 other Metastatic Solid Tumor trials with a reported enrollment target (62% lower). The listed sponsor is Valley Health System, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Zeaxanthin is the first listed.
NCT05232409 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05232409 about?
NCT05232409 is a clinical study titled "Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer". The purpose of the research is to determine the highest dose of an oral compound called zeaxanthin that can be safely taken each day in patients with advanced cancer, the toxicity profile of zeaxanthin, and the dose of zeaxanthin to use in future cancer clinical trials.
What is the current status of trial NCT05232409?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2022-04-17. Estimated completion is 2026-03.
What conditions does trial NCT05232409 study?
This clinical trial studies the following conditions: Metastatic Solid Tumor, Cancer Metastatic.
What interventions are being tested in trial NCT05232409?
The interventions under investigation include: Zeaxanthin (BIOLOGICAL), Zeaxanthin Plus Pembrolizumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05232409?
This trial is sponsored by Valley Health System, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05232409 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
RECRUITING · Phase 1
-
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.